Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma

MLA

Ya Dingv, et al. “Efficacy and Safety of Anti-PD-1 Inhibitor Combined with Nab-Paclitaxel in Chinese Patients with Refractory Melanoma.” Journal of Cancer Research and Clinical Oncology, vol. 148, no. 5, May 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e74498f8241a85bddafb8fe0aeacfd4a&authtype=sso&custid=ns315887.

APA

Ya Dingv, Hang Jiang, Jiu-Hong Wang, Xiaoshi Zhang, Dan Dan Li, Jing Jing Zhao, Xizhi Wen, Jingjing Li, Xing Liu, & Fuxue Huang. (2021). Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology, 148(5).

Chicago

Ya Dingv, Hang Jiang, Jiu-Hong Wang, Xiaoshi Zhang, Dan Dan Li, Jing Jing Zhao, Xizhi Wen, Jingjing Li, Xing Liu, and Fuxue Huang. 2021. “Efficacy and Safety of Anti-PD-1 Inhibitor Combined with Nab-Paclitaxel in Chinese Patients with Refractory Melanoma.” Journal of Cancer Research and Clinical Oncology 148 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e74498f8241a85bddafb8fe0aeacfd4a&authtype=sso&custid=ns315887.